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RESEARCH ARTICLE
The Annual Burden of Seasonal Influenza in
the US Veterans Affairs Population
Yinong Young-Xu1,2, Robertus van Aalst1*, Ellyn Russo1, Jason K. H. Lee3,4,
Ayman Chit3,4
1 Clinical Epidemiology Program, Veterans Affairs Medical Center, White River Junction, Vermont, United
States of America, 2 Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New
Hampshire, United States of America, 3 Health Outcomes and Economics, Sanofi Pasteur, Swiftwater,




Seasonal influenza epidemics have a substantial public health and economic burden in the
United States (US). On average, over 200,000 people are hospitalized and an estimated
23,000 people die from respiratory and circulatory complications associated with seasonal
influenza virus infections each year. Annual direct medical costs and indirect productivity
costs across the US have been found to average respectively at $10.4 billion and $16.3 bil-
lion. The objective of this study was to estimate the economic impact of severe influenza-
induced illness on the US Veterans Affairs population. The five-year study period included
2010 through 2014. Influenza-attributed outcomes were estimated with a statistical regres-
sion model using observed emergency department (ED) visits, hospitalizations, and deaths
from the Veterans Health Administration of the Department of Veterans Affairs (VA) elec-
tronic medical records and respiratory viral surveillance data from the Centers for Disease
Control and Prevention (CDC). Data from VA’s Managerial Cost Accounting system were
used to estimate the costs of the emergency department and hospital visits. Data from the
Bureau of Labor Statistics were used to estimate the costs of lost productivity; data on age
at death, life expectancy and economic valuations for a statistical life year were used to esti-
mate the costs of a premature death. An estimated 10,674 (95% CI 8,661–12,687) VA ED
visits, 2,538 (95% CI 2,112–2,964) VA hospitalizations, 5,522 (95% CI 4,834–6,210) all-
cause deaths, and 3,793 (95% CI 3,375–4,211) underlying respiratory or circulatory deaths
(inside and outside VA) among adult Veterans were attributable to influenza each year from
2010 through 2014. The annual value of lost productivity amounted to $27 (95% CI $24–31)
million and the annual costs for ED visits were $6.2 (95% CI $5.1–7.4) million. Ninety-six
percent of VA hospitalizations resulted in either death or a discharge to home, with annual
costs totaling $36 (95% CI $30–43) million. The remaining 4% of hospitalizations were fol-
lowed by extended care at rehabilitation and skilled nursing facilities with annual costs total-
ing $5.5 (95% CI $4.4–6.8) million. The annual monetary value of quality-adjusted life years
(QALYs) lost amounted to $1.1 (95% CI $1.0–1.2) billion. In total, the estimated annual eco-
nomic burden was $1.2 (95% CI $1.0–1.3) billion, indicating the substantial burden of
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seasonal influenza epidemics on the US Veterans Affairs population. Premature death was
found to be the largest driver of these costs, followed by hospitalization.
Introduction
Seasonal influenza epidemics continue to have a substantial public health and economic bur-
den in the United States. On average, it is estimated that over 200,000 people are hospitalized
and 23,000 people die from respiratory and circulatory complications associated with seasonal
influenza virus infections each year [1–7]. The annual direct medical costs have been found to
average $10.4 billion; indirect costs, which include estimated lost earnings due to illness and
loss of life, average $16.3 billion [5]. The total economic burden, using projected statistical life
values of seasonal influenza epidemics, is estimated to be as high as $87 billion each year.
The burden of illness caused by seasonal influenza varies by age and the presence of preex-
isting medical conditions. Serious medical complications leading to hospitalizations and
deaths are typically greatest among persons aged 65 years and older, as has been shown previ-
ously with influenza-attributed hospitalization rates. High-risk persons aged 18 to 49, 50 to 64,
and 65 and older illustrated rates of 4.0, 12.3, and 55.6, respectively, per 10,000 person-periods
[4]; in contrast, rates among low-risk adults were 0.5, 1.8, and 18.7 per 10,000 person-periods,
respectively.
Though the impact of seasonal influenza epidemics has been studied for the general popula-
tion, there is a paucity of literature describing the burden of illness and associated costs attrib-
uted to this viral infection for the US Veterans Affairs population. The Veterans Health
Administration of the Department of Veterans Affairs (VA) serves an older patient population
that is predominantly male and has a higher disease burden than the general US population
[8]. Leveraging previously described methodologies, the objective of this study was to estimate
the economic impact of severe influenza-induced illness on US Veterans Affairs population
over a five-year period from 2010 to 2014.
Materials and Methods
Study data
This study used data from VA, which is the largest integrated healthcare system in the US and
provides comprehensive health services to US Veterans. VA has an integrated and unified elec-
tronic medical record system (EMR) that contains information about inpatient, outpatient,
and emergency department (ED) visits. This includes procedures, surgeries and diagnoses,
pharmacy, laboratory results, extended care, vital signs, healthcare-related survey data and
mortality for all persons treated within VA. Each patient is assigned a unique identification
number that allows longitudinal follow-up.
VA uses a separate electronic Managerial Cost Accounting system (MCA) to capture the
cost of healthcare services. Costs are not based on insurance claims, reimbursements or billing
data; rather, they are the allocation of actual expenses (e.g. salaries, equipment, buildings,
energy, negotiated drug prices, materials) to a specific healthcare encounter. Unlike claims
data, such as those used by the Centers for Medicare and Medicaid Services, VA expense data
are not subject to variation in coding practices. Data on Veteran mortality are likewise consis-
tent, as VA Vital Status files incorporate information through multiple sources that include the
National Death Index (NDI) and capture deaths that occur at VA, as well as non-VA locations,
including at home or non-VA facilities.
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The study observation period encompassed five respiratory seasons from 2010/11 through
2014/15 (simplified as 2010 to 2014). A respiratory season was defined as starting in calendar
week 27 during a given year and ending in calendar week 26 of the following year. For exam-
ple, respiratory season 2010/11 started June 27, 2010 and lasted through June 25, 2011. The
study population was comprised of Veterans aged 18 and older enrolled at VA. To ensure we
included those who received non-incidental care, patients were eligible for inclusion in a given
respiratory season only if they had at least one inpatient or outpatient VA healthcare encounter
during the prior respiratory season. Patients were classified into three groups for each season
based on age, which was calculated at the end of the respiratory season or death: 18 to 49, 50 to
64, and 65 and older. Patients were also classified each season as at high-risk or at low-risk for
influenza-related complications; this categorization was based on the presence of one or more
primary International Classification of Diseases—9th edition (ICD-9-CM) diagnosis codes
from an inpatient or outpatient encounter during the prior respiratory season. Patients
assigned diagnosis codes for chronic cardiac, pulmonary, renal, metabolic, liver, or neurologi-
cal diseases; diabetes mellitus; hemoglobinopathies; and/or immunosuppressive conditions
and malignancy were at high-risk [4]. Patients for whom we did not find an encounter with
one of these diagnosis codes (S1 Table) were classified as at low-risk.
This study was approved by the Veteran’s Institutional Review Board of Northern New
England (VINNE) through expedited review for the use of protected health information (PHI)
as it was deemed to involve no more than minimal risk to the privacy of individuals (CPHS
28523). All study procedures were carried out in compliance with federal and institutional eth-
ical standards as well as the Helsinki Declaration. The usual requirements for HIPAA authori-
zation and study participants’ written or verbal informed consent were waived by VINNE.
Such waivers may be granted by regulatory committees when a research study meets all of the
following criteria:
1. The use or disclosure of the PHI involves no more than minimum risk to the privacy of
individuals, based on, at least, the presence of all the following elements:
a. An adequate plan to protect the identifiers from improper use and disclosure.
b. An adequate plan to destroy the identifiers at the earliest opportunity consistent with
conduct of research, unless there is a health or research justification for retaining the
identifiers or such retention is otherwise required by law.
c. Adequate written assurances that the PHI will not be reused or disclosed to any other
person or entity, except as required by law, for authorized oversight of the research
study, or for other research for which the use or disclosure of PHI would be permitted
by the HIPAA Privacy Rule.
2. The research could not practicably be conducted without the waiver or alteration.
3. The research could not practicably be conducted without access to and use of the PHI.
Estimating influenza-attributed outcomes
Influenza-attributed outcomes were categorized as follows: (1) ED visit; (2) hospitalization;
and (3) followed by death (all-cause or with underlying respiratory or circulatory causes). Sim-
ilar to previously published research methods, a negative-binomial regression model was
employed to generate weekly rates for each outcome category by risk and age group as the dif-
ference between the model-predicted outcomes and the model-predicted outcomes under the
hypothetical absence of influenza (estimated baseline), which were then totaled over the length
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of the respiratory season [2]. Annual estimates were defined as rates per 100,000 person-peri-
ods (respiratory seasons) averaged over the five year study period. The regression model, fit
using PROC GENMOD, SAS Enterprise Guide, version 6.1, with the dispersion parameter,
was:








þ b8½AðH1N1Þ þ b9½AðH3N2Þ þ b10½AðH1N12009Þ þ b11½B þ b12½RSVg
where Y represents the weekly number of influenza-attributed outcomes (VA ED visits, VA
hospitalizations or all-cause deaths) for each risk and age group, α the offset term (equals to
the size of the risk and age group-specific population), β0 the intercept, β1 the linear time
trend, β2 through β5 the non-linear time trend, β6 and β7 the seasonal changes in outcomes, β8
through β11 the weekly percentage of tests positive for each influenza virus type and subtype (t)
and β12 the weekly percentage of tests positive for respiratory syncytial virus (RSV). Publicly
available weekly influenza surveillance data, including RSV-specific surveillance data obtained
directly from the CDC, were used in the model [9]. Additional parameter details are described
in S1 Table.
To estimate excess VA ED visits and VA hospitalizations, only those healthcare encounters
at a VA facility with a principal diagnosis of underlying respiratory or circulatory conditions
(ICD-9-CM codes 390–519) were included in the model [6–7,10]. The modeled excess deaths
initially included those from all causes, and later was adjusted for underlying respiratory and
circulatory causes based on a random sample with cause of death.
Estimating the cost per influenza-attributed encounter
For each influenza-attributed VA ED visit identified, direct medical costs were defined as the
sum of the ED costs on the corresponding visit date, including expenses related to office visits,
professional consults, prescription medications and laboratory tests, imaging and procedures
performed.
VA hospitalizations were categorized by whether or not an episode of extended care fol-
lowed the discharge. For each influenza-attributed VA hospitalization without extended care
identified, direct medical costs were defined as the sum of the inpatient costs from the date of
admission to the date of discharge at an acute care facility. For each influenza-attributed VA
hospitalization with extended care identified, direct medical costs were defined as the sum of
the inpatient, rehabilitation and/or skilled nursing facility costs if the extended care stay began
immediately (within 24 hours) following the discharge from an acute care facility.
Direct medical costs for an influenza-attributed encounter defined above were extracted
from VA MCA data for those events with a principal diagnosis of underlying influenza and
pneumonia (ICD-9-CM codes 480–487) that occurred during each respiratory season [5]. Esti-
mates of encounter-specific direct medical costs were calculated by risk and age group for each
respiratory season; results are presented as the average over the five year study period.
Estimating the economic burden of seasonal influenza epidemics
Data from the US Department of Labor Bureau of Labor Statistics were used to estimate the
annual economic burden of productivity loss due to the absence from work [11]. For hospitali-
zations, the annual estimate of outcome events was multiplied by the 2014 (most resent data
available) mean Veteran occupation rates of 73.8%, 64.8%, and 18.8% for age groups 18 to 49,
50 to 64, and 65 and older, respectively; by the 2014 mean daily occupational wage of $182;
and by the mean length of stay in days for each risk and age group (S1 Table) [11–12]. For ED
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visits, a length of stay of one day was assumed. To estimate productivity loss caused by mortal-
ity, length of stay was replaced with a three month friction period [13].
To estimate the annual economic burden of influenza-attributed ED visits and hospitaliza-
tions, the annual estimate of outcome events was multiplied by the mean cost per outcome
event for each risk and age group.
We used previously described methods to estimate the annual economic burden of influ-
enza-attributed deaths [14]. Life years lost were derived for mortalities observed in the study
population using US Department of Health and Human Services Life Tables [15]. Each life
year lost was adjusted with the appropriate age- and gender-specific utility value to determine
the all-cause quality-adjusted life years (QALYs) lost by patient; these were summed to annual
totals for each risk and age group [16]. The all-cause QALYs lost were then multiplied by the
proportion of estimated influenza-attributed deaths from the rates found through the model-
ing technique described above to determine influenza-attributed QALYs lost. Lastly, the value
of influenza-attributed QALYs was calculated by multiplying the annual estimate of QALYs
lost for each risk and age group with the value of $150,000 per QALY [17].
Removal of outliers
In order to further increase the accuracy of estimated medical costs attributable to influenza,
and to reduce the impact that erroneous data and rare-but-extreme values might have on the
estimates, we imposed restrictions to the dataset [18]. Outliers for length of stay and medical
costs were excluded using statistical distributions equivalent to at least two standard deviations
from the mean in a normal distribution. These calculated exclusion criteria are as follows: (1)
ED visits which cost less than $100 (below 1st percentile) or more than $1,500 (above 99th per-
centile); (2) hospitalizations which cost less than $2,000 (below 2nd percentile) or more than
$95,000 (above 98th percentile); (3) hospitalizations with a length of stay over 28 days (above
98th percentile); and, (4) hospitalizations followed by extended care with a length of stay over
450 days (above 98th percentile).
Respiratory or circulatory causes of death
Influenza-attributed all-cause mortality estimates, as generated from the analysis described
above, include those that may not be directly associated with influenza, such as accidental
deaths. To provide more accurate estimates, deaths were categorized as those with a respira-
tory or circulatory cause and those without; deaths with a cardiorespiratory cause are pre-
sumed to be more directly associated with influenza. Because cause of death was not available
for the majority of deaths, we instead applied an adjustment to the all-cause mortality model,
which involved multiplying the observed deaths per week by the average proportion of deaths
per calendar week due to respiratory or circulatory conditions. The average proportion was
calculated from a random sample of 13,000 VA enrolled Veterans for whom cause of death
data were available from 2010 to 2014. Furthermore, by calculating the proportion per calen-
dar week, we were able to account for seasonal variation in the cardiorespiratory proportion of
all mortality.
Alternative values of QALY
Death associated with influenza is a major driver of the total annual economic burden on the
US. Therefore, the impact of a range of valuations for the monetary value of a QALY on the
total annual economic burden estimates were also explored. To account for varying opinions
on the value of a QALY, four alternate values of $250,000, $200,000, $100,000 and $50,000 per
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QALY were applied to the economic burden of influenza-attributed mortality calculations
[16,19].
Results
Over the five-year observation period, the number of patients in the study population rose for
each respiratory season from 5,294,641 patients in 2010 to 5,754,615 patients in 2014 –an
increase of nearly 9% (S2 Table). The proportion of patients that identified as female increased
slightly from 9.0% in 2010 to 9.7% in 2014. The proportion of patients aged 65 or older
increased as well from 48.2% in 2010 to 53.7% in 2014 (p<0.0001). Notably, the proportion of
patients classified as at high-risk for influenza-related complications averaged 11.0% for the 18
to 49 age group, 36.5% for the 50 to 64 cohort and 49.3% for the 65 and older group, decreasing
slightly by 1%, 4%, and 1% for each, respectively, over the five years.
Influenza-attributed outcomes
Annual mean influenza-attributed outcome estimates averaged over the five year study period
were determined to be 10,674 (95% CI 8,661–12,687) for VA ED visits, 2,538 (95% CI 2,112–
2,964) for VA hospitalizations, 5,522 (95% CI 4,834–6,210) for all-cause deaths and 3,793 (95%
CI 3,375–4,211) for respiratory or circulatory deaths (Tables 1–5, S1 and S2 Figs). Overall,
4.4% of ED visits were attributed to patients aged 18 to 49, 30.0% by those aged 50 to 64, and
65.6% by those aged 65 and older. Patients aged 18 to 49, and 50 to 64, accounted for 5.0% and
14.9%, respectively, of the observed hospitalizations; the patients aged 65 and older were
responsible for the remaining 80.1% of hospitalizations. Only 1.8% of influenza-attributed
deaths befell patients aged 18 to 49, while 18.9% befell those aged 50 to 64 and 79.3% aged 65
and older. The proportions of influenza-attributed deaths from all-cause deaths were calcu-
lated to be 9.2%, 6.3% and 4.1% for those aged 18 to 49, 50 to 64, and 65 and older, respectively,
in the high-risk group. In the low-risk group, the proportions were respectively 0.05%, 0.29%
and 0.73% (Table 5).
Table 1. Annual estimates of influenza-attributed ED visits1 by risk and age group averaged over five respiratory seasons.
Risk Age N 95% CI Person-periods Rate per 100,000 person-periods 95% CI
Lower Upper Lower Upper
High 18–49 186 132 241 128,037 146 103 188
50–64 2,843 2,348 3,339 553,798 513 424 603
65+ 6,702 5,608 7,796 1,408,113 476 398 554
Total 9,732 8,087 11,376 2,089,948 466 387 544
Low 18–49 291 180 401 1,040,587 28 17 39
50–64 354 221 486 964,133 37 23 50
65+ 298 172 424 1,445,967 21 12 29
Total 942 574 1,311 3,450,687 27 17 38
Both 18–49 477 312 642 1,168,625 41 27 55
50–64 3,197 2,569 3,825 1,517,931 211 169 252
65+ 7,000 5,780 8,220 2,854,080 245 203 288
Total 10,674 8,661 12,687 5,540,636 193 156 229
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
1Events included here are those with a principal diagnosis of underlying respiratory or circulatory conditions (ICD-9-CM codes 390–519).
doi:10.1371/journal.pone.0169344.t001
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Cost per influenza-attributed encounter
Annual mean estimates of direct medical costs for influenza-attributed ED visits averaged over
the five year study period were similar across both risk and age groups, ranging from $592 in
the high-risk 65 and older age group to $568 in the low-risk 50 to 64 age group (Table 6). For
hospitalizations without extended care, the mean direct medical costs increased across age
groups for both the high- and low-risk groups. In the high-risk group, the means were
$13,673, $14,623 and $14,839 for those aged 18 to 49, 50 to 64 and 65 and older, respectively.
In the low-risk group, the respective means were $10,872, $13,705 and $14,723. The mean
direct medical costs varied across both risk and age groups for hospitalizations with extended
Table 2. Annual estimates of influenza-attributed hospitalizations1 by risk and age group averaged over five respiratory seasons.
Risk Age N 95% CI Person-periods Rate per 100,00 person-periods 95% CI
Lower Upper Lower Upper
High 18–49 127 110 143 128,037 99 86 112
50–64 374 301 446 553,798 67 54 81
65+ 2,029 1,706 2,351 1,408,113 144 121 167
Total 2,529 2,118 2,940 2,089,948 121 101 141
Low 18–49 1 0 3 1,040,587 0 0 0
50–64 3 0 10 964,133 0 0 1
65+ 4 0 12 1,445,967 0 0 1
Total 9 0 24 3,450,687 0 0 1
Both 18–49 128 110 145 1,168,625 11 9 12
50–64 377 299 456 1,517,931 25 20 30
65+ 2,033 1,702 2,363 2,854,080 71 60 83
Total 2,538 2,112 2,964 5,540,636 46 38 53
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
1Events included here are those with a principal diagnosis of underlying respiratory or circulatory conditions (ICD-9-CM codes 390–519).
doi:10.1371/journal.pone.0169344.t002
Table 3. Annual estimates of influenza-attributed all-cause mortality by risk and age group averaged over five respiratory seasons.
Risk Age N 95% CI Person-periods Rate per 100,000 person-periods 95% CI
Lower Upper Lower Upper
High 18–49 100 91 109 128,037 78 71 85
50–64 1,017 898 1,137 553,798 184 162 205
65+ 3,940 3,485 4,394 1,408,113 280 247 312
Total 5,057 4,474 5,641 2,089,948 242 214 270
Low 18–49 1 0 2 1,040,587 0 0 0
50–64 23 17 29 964,133 2 2 3
65+ 441 343 538 1,445,967 30 24 37
Total 465 360 570 3,450,687 13 10 17
Both 18–49 101 91 111 1,168,625 9 8 10
50–64 1,041 915 1,166 1,517,931 69 60 77
65+ 4,380 3,828 4,933 2,854,080 153 134 173
Total 5,522 4,834 6,210 5,540,636 100 87 112
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t003
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care, ranging from $49,058 in the high-risk 18 to 49 age group to $73,233 in the low-risk 50 to
64 age group. The means were highest for the 50 to 64 age groups in both risk categories.
Ninety six percent of influenza-attributed hospitalizations resulted in a discharge to home
or death, while the remaining 4% were followed by extended care at rehabilitation and/or
skilled nursing facilities. The mean length of stay averaged over the five year study period for
hospitalizations without extended care ranged from 4 to 6 days across the risk and age groups;
for hospitalizations with extended care, the mean length of stay ranged from 31 days in the
high-risk 18 to 49 age group to 50 days in the low-risk 50 to 64 age group (Table 7).
Table 4. Annual estimates of influenza-attributed mortality adjusted for respiratory or circulatory cause of death by risk and age group averaged
over five respiratory seasons.
Risk Age N 95% CI Person-periods Rate per 100,000 person-periods 95% CI
Lower Upper Lower Upper
High 18–49 38 34 42 128,037 30 27 33
50–64 516 455 577 553,798 93 82 104
65+ 2,786 2,513 3,060 1,408,113 198 178 217
Total 3,341 3,003 3,679 2,089,948 160 144 176
Low 18–49 10 8 12 1,040,587 1 1 1
50–64 9 6 13 964,133 1 1 1
65+ 432 358 506 1,445,967 30 25 35
Total 452 372 532 3,450,687 13 11 15
Both 18–49 49 43 54 1,168,625 4 4 5
50–64 526 461 590 1,517,931 35 30 39
65+ 3,219 2,871 3,566 2,854,080 113 101 125
Total 3,793 3,375 4,211 5,540,636 68 61 76
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t004
Table 5. Annual estimates of influenza-attributed all-cause mortality and influenza-attributed mortality adjusted for respiratory or circulatory
cause of death as the proportion of all deaths by risk and age group averaged over five respiratory seasons.
Risk Age N, Influenza Attributed Deaths N, All Deaths Proportion (%) of All
All-cause Adjusted All-cause Adjusted
High 18–49 100 38 1,086 9.21 3.50
50–64 1,017 516 16,062 6.33 3.21
65+ 3,940 2,786 97,028 4.06 2.87
Total 5,057 3,341 114,176 4.43 2.93
Low 18–49 1 10 2,214 0.05 0.45
50–64 23 9 7,986 0.29 0.11
65+ 441 432 60,068 0.73 0.72
Total 465 452 70,268 0.66 0.64
Both 18–49 101 49 3,299 3.06 1.49
50–64 1,041 526 24,048 4.33 2.19
65+ 4,380 3,219 157,096 2.79 2.05
Total 5,522 3,793 184,444 2.99 2.06
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t005
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Economic burden of seasonal influenza epidemics in the VA population
Projected annual estimates of lost productivity for influenza-attributed ED visits, hospitaliza-
tions, hospitalizations with extended care and all-cause mortality averaged over the five year
study period were $590 (95% CI $487–693) thousand, $626 (95% CI $517–746) thousand,
$197 (95% CI $143–261) thousand and $25,758 (95% CI $22,600–28,909) thousand, respec-
tively (Table 8). While those aged 65 and older carried the majority of the lost productivity
burden caused by hospitalizations, hospitalizations with extended care and mortality (56%,
53% and 52%, respectively), those aged 50 to 64 carried the majority of the lost productivity
burden caused by ED visits (57%).
Projected annual estimates of direct medical costs for influenza-attributed ED visits, hospi-
talizations, and hospitalizations with extended care averaged over the five year study period
were $6.2 (95% CI $5.1–7.4) million, $36.1 (95% CI $29.8–42.7) million and $5.5 (95% CI
$4.4–6.8) million, respectively (Table 9). Overall, 4.4% of ED visit costs were accounted for by
those aged 18 to 49, 29.2% by those aged 50 to 64, and 66.4% by those aged 65 and older. For
hospitalizations without extended care costs, patients aged 18 to 49 and those aged 50 to 64
accounted for 4.7% and 15.1%, and those aged 65 and older accounted for 80.2%. Finally, 2.3%
of hospitalizations with extended care costs were accounted for by those aged 18 to 49, 4.0% by
those aged 50 to 64, and 93.7% by those aged 65 and older.
The annual monetary value of QALYs lost caused by influenza-attributed all-cause
deaths averaged over the five year study period amounted to $1.1 (95% CI $1.0–1.2) billion
Table 6. Annual estimates of influenza-attributed direct medical costs for healthcare encounters by risk and age group in US Dollars averaged
over five respiratory seasons.
Risk Age ED Visit Hospitalization Only Hospitalization with Extended Care
Mean 95% CI Mean 95% CI Mean 95% CI
Lower Upper Lower Upper Lower Upper
High 18–49 574 570 577 13,673 12,959 14,386 49,058 18,164 79,951
50–64 571 570 573 14,623 14,400 14,846 70,701 63,923 77,480
65+ 592 591 593 14,839 14,720 14,958 63,921 61,309 66,534
Low 18–49 569 567 571 10,872 10,301 11,442 61,688 37,830 85,545
50–64 568 566 570 13,705 13,339 14,072 73,233 64,085 82,381
65+ 590 589 592 14,723 14,454 14,992 60,526 55,570 65,482
doi:10.1371/journal.pone.0169344.t006
Table 7. Mean length of stay for hospitalizations without and with extended care1 by risk and age group in days averaged over five respiratory
seasons.
Risk Age Hospitalization Only Hospitalization with Extended Care
N Mean 95% CI N Mean 95% CI
Lower Upper Lower Upper
High 18–49 1,368 4.5 4.3 4.7 11 31 7 56
50–64 14,724 4.9 4.9 5 393 47 41 53
65+ 47,811 5.2 5.2 5.3 1,984 41 39 44
Low 18–49 1,575 3.8 3.7 4 15 35 18 52
50–64 5,370 4.8 4.7 4.9 110 50 41 59
65+ 10,114 5.4 5.3 5.5 453 43 38 48
1Events included here are those with a principal diagnosis of underlying influenza and pneumonia (ICD-9-CM codes 480–487).
doi:10.1371/journal.pone.0169344.t007
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(Table 10). The proportion of the monetized QALY loss across risk and age groups was highest
for those aged 50 to 64 (71.5% for high-risk and 82.3% for low-risk), followed next by those
aged 18 to 49 (27.9% for high and 15.6% for low risk), and smallest for those aged 65 and older
(0.53% for high and 2.1% for low). The total annual economic burden, determined by adding
the estimates of lost productivity, direct medical costs and the monetary value of QALYs lost,
was $1.2 (95% CI $1.0–1.3) billion (Table 11).
Sensitivity analyses
Using a combination of the lowest valuation of a QALY and respiratory or circulatory causes
of death, the total annual economic burden amounted to $251 (95% CI $217–285) million.
Alternatively, when using all-cause mortality and the highest valuation of a QALY, the estimate
totaled $1.9 (95% CI $1.7–2.1) billion (Table 12).
Table 8. Annual estimates of lost productivity for influenza-attributed healthcare encounters and all-cause mortality by age group in thousands of
US Dollars averaged over five respiratory seasons.
Age ED Visit Hospitalization Only Hospitalization with Extended
Care
All-cause Mortality
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
18–49 25.0 17.7 32.4 69.1 57.7 81.6 10.0 3.5 18.2 1,221 1,100 1,342
50–64 335 277 394 207 165 251 82 57 111 11,049 9,712 12,376
65+ 229 192 267 350 293 413 105 83 132 13,488 11,788 15,191
Total 590 487 693 626 517 746 197 143 261 25,758 22,600 28,909
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t008
Table 9. Annual estimates of influenza-attributed direct medical costs for healthcare encounters by risk and age group in thousands of US Dollars
averaged over five respiratory seasons.
Risk Age ED Visit Hospitalization Only Hospitalization with Extended Care
Mean 95% CI Mean 95% CI Mean 95% CI
Lower Upper Lower Upper Lower Upper
High 18–49 107 75 139 1,702 1,397 2,016 125 40 229
50–64 1,623 1,338 1,913 5,425 4,300 6,568 211 153 276
65+ 3,968 3,314 4,623 28,909 24,112 33,765 5,168 4,167 6,232
Total 5,698 4,728 6,675 36,036 29,808 42,350 5,503 4,361 6,737
Low 18–49 166 102 229 11 0 34 1 0 2
50–64 201 125 277 39 0 135 9 0 35
65+ 176 101 251 57 0 175 6 0 20
Total 542 328 757 107 0 344 16 0 58
Both 18–49 272 177 368 1,712 1,397 2,050 126 40 232
50–64 1,824 1,463 2,190 5,465 4,300 6,703 220 153 311
65+ 4,143 3,416 4,874 28,966 24,112 33,940 5,174 4,167 6,253
Total 6,240 5,056 7,432 36,143 29,808 42,693 5,520 4,361 6,796
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t009
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Table 10. Annual estimates of influenza-attributed life years lost, quality adjusted life years (QALYs) lost and monetary value of QALYs lost by
risk and age group in millions of US Dollars averaged over five respiratory seasons.
Risk Age Life Years Lost QALYs Lost Value of QALYs Lost
N 95% CI N 95% CI Mean 95% CI
Lower Upper Lower Upper Lower Upper
High 18–49 2,686 2,444 2,927 2,009 1,829 2,190 301 274 329
50–64 6,423 5,672 7,181 5,139 4,538 5,746 771 681 862
65+ 25.1 22.2 27.9 38.2 33.8 42.6 5.7 5.1 6.4
Total 9,134 8,138 10,136 7,187 6,401 7,979 1,078 960 1,197
Low 18–49 27 0.0 53 25 0.0 50 3.8 0.0 7.5
50–64 168 124 211 136 101 171 20 15 26
65+ 2.0 1.6 2.5 3.1 2.4 3.7 0.5 0.4 0.6
Total 196 126 267 164 103 226 25 15 34
Both 18–49 2,712 2,444 2,981 2,035 1,829 2,241 305 274 336
50–64 6,591 5,796 7,393 5,275 4,639 5,917 791 696 888
65+ 27.1 23.7 30.4 41.3 36.2 46.3 6.2 5.4 7.0
Total 9,330 8,263 10,404 7,351 6,503 8,204 1,103 976 1,231
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t010
Table 11. Annual estimates of economic burden using direct medical costs, lost productivity and monetary value of quality adjusted life years
(QALYs) lost based on all-cause influenza-attributed mortality by age group in millions of US Dollars averaged over five respiratory seasons.
Age Direct Medical Costs Lost Productivity Value of QALYs Lost Total Economic Burden
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper
18–49 2.1 1.6 2.6 1.3 1.2 1.5 305 274 336 309 277 340
50–64 7.5 5.9 9.2 12 10 13 791 696 888 810 712 910
65+ 38 32 45 14 12 16 6.2 5.4 7.0 59 49 68
Total 48 39 57 27 24 31 1,103 976 1,231 1,178 1,038 1,318
Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
doi:10.1371/journal.pone.0169344.t011
Table 12. Sensitivity analysis to estimate the annual economic burden using direct medical costs, lost productivity and monetary value of quality
adjusted life years (QALYs) lost for different monetary values per QALY by all-cause and respiratory or circulatory cause of death adjusted influ-
enza-attributed mortality and age group in millions of US Dollars.
Mortality Age $250,000 per QALY $200,000 per QALY $150,000 per QALY $100,000 per QALY $50,000 per QALY
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Lower Upper Lower Upper Lower Upper Lower Upper Lower Upper
All-cause 18–49 512 460 564 410 369 452 309 277 340 207 186 228 105 94 116
50–64 1,338 1,176 1,502 1,074 944 1,206 810 712 910 547 480 614 283 248 318
65+ 63 53 73 61 51 70 59 49 68 57 48 66 55 46 63
Total 1,913 1,689 2,139 1,545 1,364 1,728 1,178 1,038 1,318 810 713 908 443 388 498
Adjusted 18–49 257 223 290 206 179 233 155 135 175 104 91 118 54 46 61
50–64 679 595 764 546 478 615 413 362 465 280 245 315 147 128 166
65+ 56 48 65 55 46 63 53 45 62 52 44 60 50 42 59
Total 992 866 1,119 807 704 911 621 542 702 436 379 494 251 217 285
doi:10.1371/journal.pone.0169344.t012
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Discussion
Building on previously published research methods for estimating influenza-attributed urgent
healthcare utilization (ED visits and hospitalizations), mortality and costs, this investigation
presents an up-to-date assessment of the annual seasonal influenza epidemic burden in the US
Veterans Affairs population. As the largest integrated healthcare system in the US, services
provided to Veterans at VA can be followed across the care continuum from the non-urgent
outpatient clinic to the ED and subsequent hospitalization, as well as post-discharge extended
care in rehabilitation and nursing facilities. The analytical dataset used here therefore encom-
passes the majority of a patient’s VA healthcare and costs. We found 10,674 VA ED visits with
costs amounting to $6.2 million, 2,538 VA hospitalizations with costs amounting to $41.7 mil-
lion and 5,522 all-cause deaths with monetary losses amounting to $1.1 billion averaged over
the five year study period from 2010 to 2014. Combined, these result in an estimated total
annual influenza-attributed societal burden of $1.2 billion.
Consistent with previously reported results on the general US population, the annual bur-
den of illness caused by seasonal influenza virus infections varied by both risk and age groups
and was found to be greatest for those aged 65 and older and at high-risk for complications as
based on the presence of certain co-existing medical conditions [1–7]. While ED visits and
costs were closer among the three age groups than the other outcome event categories, overall,
they differed greatly by risk, with those aged 65 and older at high-risk accounting for more of
the visits than those aged 18 to 49 at low-risk. Similar findings have been reported by Schanzer
and colleagues for the Canadian population [20]. The majority of the hospitalizations and
deaths occurred for patients aged 65 and older, regardless of risk stratification; thus, most of
the hospitalization costs and productivity losses were incurred by those aged 65 and older.
However, the monetary value of QALYs lost was considerably smaller for this group than for
both the 18 to 49 and 50 to 64 age groups. Overall, premature death was found to be the largest
driver of costs, followed by hospitalization.
Limitations
First, the negative-binomial model used in our analysis was thought to be most appropriate for
the over-dispersed data under study and is otherwise similar to the Serfling-Poisson model
that has been employed more widely for these types of estimations. Limitations of these meth-
ods have been described previously and include (1) the accuracy of identifying outcome events
based on the presence of a principal diagnosis code from an observed healthcare encounter,
which may not account for influenza’s contribution to prompt an individual to seek urgent or
emergent care for other conditions or events that are therefore coded as the primary diagnosis;
(2) the dependence on coding practices to identify observed outcome events, which may be
influenced by a lack of coding resources (e.g. time and skill); and (3) the attribution of all
excess outcomes to influenza when confounding, such as the presence of other respiratory
viruses like the human metapneumovirus, is possible and may result in an over-estimation of
the outcome events [2–7,20–21]. In addition, our estimation of underlying respiratory or cir-
culatory deaths attributable to influenza, although based on a large random sample, is poten-
tially susceptible to bias as we have not verified that the sample is representative of all VA
deaths. Lastly, outliers in the cost data were excluded here in order to mitigate our concerns
surrounding the impact that erroneous data and rare-but-extreme values may have on the
estimates.
Second, it is difficult to compare the results found through this analysis directly with those
reported in previously published studies. The US Veterans Affairs population differs from the
US general population in terms not only of size (and growth over time), but in age, gender,
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and health status [8]. Furthermore, the healthcare systems differ in terms of organization and
cost across populations under study. The estimates are reported as annual means over a five-
year observation period from 2010 to 2014; many of the related earlier studies were performed
with data through respiratory season 2010 only and not from the VA population [2–7].
Third, our methods for cost accounting were more conservative than some of the previous
similar studies. Most notably, costs were limited to the day of an ED visit and the acute or
extended care portion of a hospitalization and discharge. Others, such as Molinari and col-
leagues, have used a window of two weeks prior to and up to 30 days following discharge for
these calculations, as well as direct medical costs associated with an outcome of death [5].
Additionally, VA cost data represent actual expense figures, not insurance claims, which have
been shown to be lower than the cost paid by CMS for similar services [22–24]. Also, our
healthcare encounter data are partial, including those that occurred at VA facilities but not
those at non-VA facilities [25]. In contrast, our mortality data are complete. As such, it is likely
that our results underestimate the influenza-attributed healthcare encounters that Veterans
experience, while they over-estimate the number of influenza-attributed deaths. Finally, VA-
specific influenza surveillance data, cause of death and VA-specific utility values for calculating
QALYs lost were not available when these analyses were performed. Furthermore, the propor-
tion of employed hospitalized Veterans may be lower than the average we used, leading to a
possible over-estimation of the economic burden; however, we did not include wages lost by
the Veterans’ caregivers, which may, conversely, lead to an under-estimation of the economic
burden.
Conclusion
Using five respiratory seasons of data, this study provided an assessment of the burden of
influenza epidemics in the US Veterans Affairs population. Over the study period we estimated
over 13,000 VA influenza-attributed healthcare encounters, more than 5,000 influenza-attrib-
uted deaths, $48 million in direct medical costs to VA and a projected cost to society of $1.2
billion occur each year. Future research efforts to evaluate the impact of immunization on this
burden and identify opportunities by which to enhance prevention efforts for this population
are warranted.
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